Researchers at the University of Rochester have developed a novel 3D retinal organoid model derived from human pluripotent stem cells to study vision loss in CLN3 disease, revealing that non-neuronal retinal pigment epithelium (RPE) cell dysfunction alone can drive photoreceptor degeneration, according to retinal and neurodegenerative researcher Ruchira Singh.
Why CLN3 Disease Vision Loss Precedes Neurological Decline
CLN3 disease is the most common form of Batten disease, driven by mutations in the CLN3 gene. According to Ruchira Singh, a researcher at the University of Rochester interviewed by DDN, vision loss is typically the earliest symptom in early childhood. It often precedes neurological decline by years, changing a child’s ability to read, learn, and move independently. CLN3 is a rare, fatal inherited disorder of the nervous system causing progressive mental and physical decline. Scientists previously struggled to study this early vision loss because human in vitro models could not represent the spatial organization between photoreceptors and RPE cells.
How the 3D Retina Organoid Model Reproduces Pathology
To overcome past limitations, Singh’s lab created a 3D retinal organoid model from human pluripotent stem cells. According to Singh, the model successfully reproduces the earliest and most consistent pathology seen in patients: the disorganization and loss of photoreceptor outer segments. This approach allowed researchers to capture outer retina pathology that mouse models had never captured. Unlike 2D cultures lacking photoreceptor-RPE interactions or animal models where every cell carries the mutation, the 3D human model allowed defined combinations of mutant and control cell types.
Did You Know?
In CLN3 disease, RPE cells form a single layer that protects and supports photoreceptor nerve cells.
Testing Recombinant Human Acid Ceramidase as a Treatment
The 3D retina model helped the research team identify a potential new treatment strategy by revealing that reduced acid ceramidase levels act as a molecular driver of photoreceptor degeneration. Based on this mechanism, the team tested enzyme replacement therapy with recombinant human acid ceramidase (rhAC). According to Singh, rhAC led to improvements in the cellular health of photoreceptor cells in both the 3D retina model and a miniswine model.
Because rhAC has already been studied for over a decade as an enzyme replacement therapy in Farber disease, its application for CLN3 disease may face fewer hurdles. Singh noted that delivery could occur via intravitreal injection rather than systemically. This route avoids getting a large enzyme across the blood-retina barrier, and intravitreal injection is already routine in ophthalmology.
Next Steps for Preclinical Optimization
Before clinical testing can begin, Singh and her team must optimize intravitreal rhAC delivery in their miniswine model and determine the precise dose required for a longer duration therapeutic effect. According to Singh, the team is actively seeking funding support to address this gap between the identified mechanism and treatments that could eventually reach patients. Moving forward, the lab plans to use the 3D model to directly compare the therapeutic efficacy of rhAC against other potential treatments.
Frequently Asked Questions
What is CLN3 disease?
CLN3 disease is the most common form of Batten disease, caused by mutations in the CLN3 gene. It is a rare, fatal inherited nervous system disorder that typically begins in childhood and causes progressive mental and physical decline.
Why is vision loss an early symptom of CLN3 disease?
According to research from the University of Rochester, vision loss usually precedes neurological decline by years. Recent 3D organoid models show that RPE cell dysfunction in the outer retina drives photoreceptor degeneration independently.
How does recombinant human acid ceramidase (rhAC) help?
rhAC acts as an enzyme replacement therapy that targets reduced acid ceramidase levels identified as a molecular driver of photoreceptor degeneration in the 3D retina model.